1. Scrip
  2. >>Business
  3. >>Deals

Teva Adds Needed LatAm Puzzle Piece With Rimsa Buy

 
• By Sten Stovall

Teva Pharmaceutical Industries Ltd seems to have outbid a number of rivals to win Mexican drugmaker Rimsa for $2.3bn cash, a move which will bolster the Israeli generics giant's presence in Latin America and position it for further acquisitions in that fast growing region.

Teva Pharmaceutical Industries Ltd seems to have outbid a number of rivals to win Mexican drugmaker Rimsa for $2.3bn cash, a move which will bolster the Israeli generics giant's presence in Latin America and position it for further acquisitions in that fast growing region.

One of the top pharmaceutical manufacturers in Mexico, Representaciones E Investigaciones Medicas SA de CV (RIMSA) has a big portfolio of specialty drugs and a core focus on developing fixed-dose combination products

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.